Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial
Olaparib, pembrolizumab, and carboplatin given as first-line treatment of RM-HNSCC resulted in a higher ORR than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.
Authors
- Jessica Ley (ORCID: https://orcid.org/0000-0001-5092-8884)
- Jingxia Liu (ORCID: https://orcid.org/0000-0002-9434-7907)
- Douglas R. Adkins (ORCID: https://orcid.org/0000-0003-3207-8227)
- Peter Oppelt (ORCID: https://orcid.org/0000-0001-6685-1762)
Institutions
- Washington University in St. Louis (US)
- Symphony Technology (United States) (US)
- Alvin J. Siteman Cancer Center (US)
Publication Details
- Journal
- JCO oncology advances.
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1200/oa-25-00049
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00